A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib

Stopped It was determined not to be needed based on the clinical development plan of Tykerb.

Conditions

• Healthy Subjects

Interventions

• DRUG: lapatinib

Sponsor

GlaxoSmithKline